Radiopharm Theranostics, Ltd
Clinical trials sponsored by Radiopharm Theranostics, Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New radioactive tracer could spot hidden tumors Results expected Sep 2026 (estimated)
- New radioactive antibody could light up Hard-to-Treat cancers Results expected Aug 2027 (estimated)
-
New radioactive tracer could spot hidden tumors
Diagnosis OngoingThis early-stage trial tests a radioactive imaging agent called RAD301 in 9 people: healthy volunteers and patients with pancreatic, lung, esophageal, cervical, endometrial, or ovarian cancer. The goal is to see how safe it is and how it travels through the body. If it works, it …
Phase 1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
New imaging agent could spot recurrent brain metastases more accurately
Diagnosis OngoingThis study tests a new imaging agent called RAD101, used with a PET scan, to see if it can better detect brain metastases that have come back after treatment. About 30 adults with certain cancers (like lung, breast, or melanoma) and suspected recurrent brain tumors will receive o…
Phase 2 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC